Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPS6KA3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPS6KA3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPS6KA3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RPS6KA3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPS6KA3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RPS6KA3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RPS6KA3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00525484 | Colorectum | FAP | regulation of endopeptidase activity | 79/2622 | 432/18723 | 7.15e-03 | 4.36e-02 | 79 |
GO:00160494 | Colorectum | CRC | cell growth | 95/2078 | 482/18723 | 1.51e-08 | 2.75e-06 | 95 |
GO:00015584 | Colorectum | CRC | regulation of cell growth | 78/2078 | 414/18723 | 1.84e-06 | 9.11e-05 | 78 |
GO:00181054 | Colorectum | CRC | peptidyl-serine phosphorylation | 61/2078 | 315/18723 | 9.88e-06 | 3.31e-04 | 61 |
GO:00064175 | Colorectum | CRC | regulation of translation | 82/2078 | 468/18723 | 1.79e-05 | 5.40e-04 | 82 |
GO:00459274 | Colorectum | CRC | positive regulation of growth | 51/2078 | 259/18723 | 3.23e-05 | 8.27e-04 | 51 |
GO:00182093 | Colorectum | CRC | peptidyl-serine modification | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00303074 | Colorectum | CRC | positive regulation of cell growth | 34/2078 | 166/18723 | 2.94e-04 | 4.67e-03 | 34 |
GO:00436204 | Colorectum | CRC | regulation of DNA-templated transcription in response to stress | 15/2078 | 53/18723 | 4.69e-04 | 6.84e-03 | 15 |
GO:20001165 | Colorectum | CRC | regulation of cysteine-type endopeptidase activity | 39/2078 | 235/18723 | 6.74e-03 | 4.77e-02 | 39 |
GO:00064177 | Liver | NAFLD | regulation of translation | 85/1882 | 468/18723 | 4.58e-08 | 4.54e-06 | 85 |
GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:00182094 | Liver | NAFLD | peptidyl-serine modification | 64/1882 | 338/18723 | 4.65e-07 | 2.89e-05 | 64 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00015585 | Liver | NAFLD | regulation of cell growth | 63/1882 | 414/18723 | 5.50e-04 | 7.46e-03 | 63 |
GO:00436207 | Liver | NAFLD | regulation of DNA-templated transcription in response to stress | 14/1882 | 53/18723 | 5.66e-04 | 7.59e-03 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS6KA3 | SNV | Missense_Mutation | | c.355N>T | p.Arg119Cys | p.R119C | P51812 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
RPS6KA3 | SNV | Missense_Mutation | | c.2038G>A | p.Val680Ile | p.V680I | P51812 | protein_coding | tolerated(0.24) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA3 | SNV | Missense_Mutation | novel | c.1399C>A | p.Leu467Ile | p.L467I | P51812 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA3 | SNV | Missense_Mutation | rs779360754 | c.1579G>A | p.Val527Ile | p.V527I | P51812 | protein_coding | tolerated(0.07) | benign(0.045) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
RPS6KA3 | SNV | Missense_Mutation | novel | c.909N>G | p.Phe303Leu | p.F303L | P51812 | protein_coding | tolerated(0.51) | benign(0.096) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
RPS6KA3 | SNV | Missense_Mutation | | c.472C>T | p.Arg158Cys | p.R158C | P51812 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
RPS6KA3 | SNV | Missense_Mutation | | c.332A>G | p.Asp111Gly | p.D111G | P51812 | protein_coding | deleterious(0) | benign(0.432) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA3 | insertion | Nonsense_Mutation | novel | c.2063_2064insGTTGTGG | p.Tyr688Ter | p.Y688* | P51812 | protein_coding | | | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
RPS6KA3 | SNV | Missense_Mutation | novel | c.1377N>A | p.Asp459Glu | p.D459E | P51812 | protein_coding | deleterious(0.03) | benign(0.13) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RPS6KA3 | SNV | Missense_Mutation | novel | c.1171N>G | p.Thr391Ala | p.T391A | P51812 | protein_coding | tolerated(0.85) | benign(0) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 249565819 | | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | GNF-PF-2301 | CHEMBL578061 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | GM-CSF | REGRAMOSTIM | 8662788 |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | LAUROGUADINE | LAUROGUADINE | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 249565718 | CHEMBL573107 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | SP-600125 | SP-600125 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PHA-767491 | CHEMBL225519 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | GS 6201 | GS 6201 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | LY-2090314 | LY-2090314 | |
6197 | RPS6KA3 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | UREA | UREA | 9458825 |